CureVac N.V (CVAC): Price and Financial Metrics
CVAC Price/Volume Stats
Current price | $2.33 | 52-week high | $12.36 |
Prev. close | $2.31 | 52-week low | $2.21 |
Day low | $2.28 | Volume | 837,600 |
Day high | $2.42 | Avg. volume | 816,585 |
50-day MA | $3.07 | Dividend yield | N/A |
200-day MA | $5.48 | Market Cap | 521.64M |
CVAC Stock Price Chart Interactive Chart >
CureVac N.V (CVAC) Company Bio
CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.(Source:Wikipedia)
Latest CVAC News From Around the Web
Below are the latest news stories about CUREVAC NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.
These Analysts Just Made A Huge Downgrade To Their CureVac N.V. (NASDAQ:CVAC) EPS ForecastsOne thing we could say about the analysts on CureVac N.V. ( NASDAQ:CVAC ) - they aren't optimistic, having just made a... |
Rebel's Edge - December 19: $RUN, $AFRM, $CVAC, and College Football RecruitsJon and Pete Najarian join forces to discuss and debate their favorite topics, including the hottest stock-specific news and sports! |
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights utilized in Comirnaty, BioNTech, and Pfizer Inc's (NYSE: PFE) mRNA COVID-19 vaccine. The ruling represents the first decision on validity in ongoing patent litigation between CureVac and BioNTech in Germany, involving eight CureVac intellectual property rights. Proc |
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SEValidity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE Decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering strong foundational ... |
UPDATE 2-German court quashes CureVac patent after challenge by BioNTechA German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. CureVac's Nasdaq-listed shares plunged 35% to a record low after the verdict. |
CVAC Price Returns
1-mo | -23.10% |
3-mo | -34.73% |
6-mo | -54.58% |
1-year | -68.39% |
3-year | -98.03% |
5-year | N/A |
YTD | -44.66% |
2023 | -30.18% |
2022 | -82.42% |
2021 | -57.68% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...